InterVenn Biosciences Announces That Arnold Levine Has Joined the Company’s Board of Advisors
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–#AI–InterVenn Biosciences today announced that Arnold Levine, Ph.D., has joined the Company’s Board of Advisors, effective March 19, 2021. Dr. Levine joins the InterVenn Board of Advisors as one of the pioneers of molecular cancer research.
Dr. Levine and others discovered the p53 tumor suppressor protein, a molecule that inhibits tumor development. He established the Simons Center for Systems Biology at the Institute for Advanced Study in Princeton, NJ, concentrating on research at the interface of molecular biology and the physical sciences: on genetics and genomics, polymorphisms and molecular aspects of evolution, signal transduction pathways and networks, stress responses, and pharmacogenomics in cancer biology.
Recognizing the potential of convergence research in the life sciences, Dr. Levine has inaugurated a program of research collaborations, in partnership with Stand Up to Cancer, and others, that brings together quantitative scientists from theoretical physics, computer science, and mathematics, with biologists and clinicians, to develop novel approaches to solve important problems in cancer research. He also leads the National Science Foundation sponsored Cancer Convergence Education Network and focuses on fostering convergence research to produce fundamental insights in the areas of immunology and infectious diseases.
Dr. Levine’s accomplishments have been acknowledged with numerous prestigious awards and prizes in the fields of oncology and immunology, with honorary doctorates from universities around the world, and with elections to the National Academy of Sciences as well as the National Academy of Medicine.
“It is clear that glycoproteomics is a rich field of potential biologic and clinical insights that has not been nearly explored at a scale consistent with genomics or even proteomics. I look forward to advising InterVenn’s research and clinical efforts to maximize the potential of their platform and resulting diagnostic solutions,” said Dr. Levine.
“We are extremely grateful to welcome Arnold to our board,” said Aldo Carrascoso, Co-Founder and Chief Executive Officer of InterVenn Biosciences. “Arnold is a widely acclaimed leader in cancer research, and we look forward to his guidance and expertise this year and in the years to come.”
About InterVenn Biosciences
InterVenn Biosciences utilizes a proprietary high-throughput glycoproteomic interrogation platform using artificial intelligence and mass spectrometry for next-gen precision medicine. The company is working to find new solutions in ovarian, pancreatic, liver, prostate, and kidney cancer, together with applications from the Vista suite of solutions for treatment and monitoring, immune profiling, patient stratification, and disease progression. For more information about InterVenn Biosciences, please visit the company’s website.
Andrea Vuturo, email@example.com, (888) 706-1670